Combination Targeted Therapy with Lenvatinib and Pembrolizumab in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers

By sjmartinez • June 27, 2024

French JD, Haugen BR, Worden FP, Bowles DW, Gianoukakis AG, Konda B, Dadu R, Sherman EJ, McCue S, Foster NR, Nikiforov YE, Farias TDJ, Norman PJ, Wirth LJ. Combination Targeted Therapy with Lenvatinib and Pembrolizumab in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers. Clin Cancer Res. 2024 Jun 26. doi: 10.1158/1078-0432.CCR-23-3417. Epub ahead of print. PMID: 38922338.

Tags: Endocrinology, Harbor UCLA, Publications

FXYD2 marks and regulates maturity of (beta) cells via ion channel-mediated signal transduction

Tacto C, Tahbaz M, Salib A, Wang S, Cayabyab F, Choi J, Kim K, Hamba Y, Perez H, Gershon PD, Damoiseaux R, Oh TG, Yoshihara[...]

Determining Insulin Pump Candidacy: The Disconnect Between Clinical Care Guidelines and Clinical Practice

Everett E, Dao L, Munaganuru N, Udeze K, Gutierrez S, Gann S, Meda A, Tiu R, Arevalo A, Drexler C, Abdulrahman Y, Santana C, Moin[...]

mTOR inhibition triggers mitochondrial fragmentation in cardiomyocytes through proteosome-dependent prohibitin degradation and OPA-1 cleavage

Verdejo HE, Parra V, Del Campo A, Vasquez-Trincado C, Gatica D, Lopez-Crisosto C, Kuzmicic J, Venegas-Zamora L, Zuñiga-Cuevas U, Troncoso MF, Troncoso R, Rothermel BA,[...]